Nykode Therapeutics AS (OTCMKTS:VACBF) Sees Significant Growth in Short Interest

Nykode Therapeutics AS (OTCMKTS:VACBF) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,887,300 shares, an increase of 77.3% from the February 29th total of 1,064,500 shares. Based on an average trading volume of 4,500 shares, the short-interest ratio is currently 419.4 days.

Nykode Therapeutics AS Stock Performance

OTCMKTS:VACBF remained flat at $1.58 during mid-day trading on Friday. The firm has a 50 day moving average of $1.58 and a two-hundred day moving average of $1.75. Nykode Therapeutics AS has a 12-month low of $1.58 and a 12-month high of $2.25.

Nykode Therapeutics AS Company Profile

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10.